Related references
Note: Only part of the references are listed.Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System
Bharati Bhardwaja et al.
BIODRUGS (2022)
The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems
Tore K. Kvien et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2022)
Use of Biosimilar Medications in Oncology
Zeina Nahleh et al.
JCO ONCOLOGY PRACTICE (2022)
Projected US Savings From Biosimilars, 2021-2025
Andrew Mulcahy et al.
AMERICAN JOURNAL OF MANAGED CARE (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
A global comparison of implementation and effectiveness of materiovigilance program: overview of regulations
Deeksha Joshi et al.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2021)
The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK
Kevin Klein et al.
DRUG SAFETY (2020)
Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea
Hye-Jae Lee et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2020)
Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
Vesa Halimi et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
Hui-Yao Huang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study
Heinz Ludwig et al.
FUTURE ONCOLOGY (2019)
Demystifying biosimilars: development, regulation and clinical use
Hope S. Rugo et al.
FUTURE ONCOLOGY (2019)
Academic oncology clinicians' understanding of biosimilars and information needed before prescribing
John W. Cook et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained
Matti Aapro et al.
BIODRUGS (2018)
FDA's Approval of the First Biosimilar to Bevacizumab
Sandra J. Casak et al.
CLINICAL CANCER RESEARCH (2018)
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
Paul Declerck et al.
CLINICAL THERAPEUTICS (2018)
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction
Ylenia Ingrasciotta et al.
DRUG SAFETY (2018)
Talking to patients about biosimilars
Yelena Y. Janjigian et al.
FUTURE ONCOLOGY (2018)
Barriers to Oncology Biosimilars Uptake in the United States
Chadi Nabhan et al.
ONCOLOGIST (2018)
Biosimilars: Review of current applications, obstacles, and their future in medicine
Flyn Kaida-Yip et al.
WORLD JOURNAL OF CLINICAL CASES (2018)
The role of biosimilars in value-based oncology care
Kashyap B. Patel et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
P2.01-039 Erythropoiesis-Stimulating Agents for Chemotherapy-Induced Anaemia in Lung Cancer: Efficacy, Toxicity and Effect on Survival
V. Xirou et al.
Journal of Thoracic Oncology (2017)
The rise of biosimilars: How they got here and where they are going
Dhiren Patel et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study)
Matti Aapro et al.
JOURNAL OF GERIATRIC ONCOLOGY (2017)
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
Shomron Ben-Horin et al.
GUT (2016)
Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody
J. D. Isaacs et al.
JOURNAL OF INTERNAL MEDICINE (2016)
Postmarket policy considerations for biosimilar oncology drugs
Matthew J. Renwick et al.
LANCET ONCOLOGY (2016)
Safety and efficacy of biosimilars in oncology
Huub Schellekens et al.
LANCET ONCOLOGY (2016)
Biosimilars: How Can Payers Get Long-Term Savings?
Jorge Mestre-Ferrandiz et al.
PHARMACOECONOMICS (2016)
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
K. Blackwell et al.
ANNALS OF ONCOLOGY (2015)
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
Lutz Heinemann et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2015)
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
Dimitra Grapsa et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Biologics and biosimilars
Palak K. Patel et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
The constrained prescription, interchangeability and substitution of biosimilars
Paola Minghetti et al.
NATURE BIOTECHNOLOGY (2015)
Comparative immunogenicity assessment: a critical consideration for biosimilar development
Patrick M. Liu et al.
BIOANALYSIS (2015)
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Shomron Ben-Horin et al.
Expert Review of Gastroenterology & Hepatology (2015)
Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
Natasha Irrera et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database
Paola M. Cutroneo et al.
DRUG SAFETY (2014)
Regulatory and clinical considerations for biosimilar oncology drugs
Charles L. Bennett et al.
LANCET ONCOLOGY (2014)
New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS)
Ju-Young Shin et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Physiology and Pharmacology of Erythropoietin
Wolfgang Jelkmann
TRANSFUSION MEDICINE AND HEMOTHERAPY (2013)
Bevacizumab treatment for advanced non-small cell lung cancer: A case report
Yun Fan et al.
ONCOLOGY LETTERS (2013)
Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States
Islah Ahmed et al.
CLINICAL THERAPEUTICS (2012)
Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance?
Marlous Kooijman et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Biosimilar agents in oncology/haematology: from approval to practice
Dietger Niederwieser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Biosimilars: pharmacovigilance and risk management
Leyre Zuniga et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Marcello Tonelli et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Pure red-cell aplasia and epoetin therapy
CL Bennett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
